AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Bicara Therapeutics Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00Z15DGL6
17.07▼ 0.54 (-3.07%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
Trailing P/E
—
Price / Sales
—
EV / Revenue
—
EV / EBITDA
Financial Highlights
Revenue (TTM)
—
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
—
Net Debt
Trading Information
Previous Close
17.61
Day's Range
16.98 – 17.85
52-Week Range
13.70 – 30.99
Volume
712.3K
Avg Volume
791.2K
Share Statistics
Shares Outstanding
Employees
103
Exchange
XNAS
Listed
2024-09-13
Share count as of August 6, 2026

Bicara Therapeutics Inc. Common Stock (BCAX) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Bicara Therapeutics Inc. Common Stock (BCAX)
What is Bicara Therapeutics Inc. Common Stock's Market Cap?
Bicara Therapeutics Inc. Common Stock's Market Cap is $1.1B, based on as-reported figures from SEC (XBRL) filings.
What is Bicara Therapeutics Inc. Common Stock's Enterprise Value?
Bicara Therapeutics Inc. Common Stock's Enterprise Value is $632.3M, based on as-reported figures from SEC (XBRL) filings.
What is Bicara Therapeutics Inc. Common Stock's EV / EBITDA?
Bicara Therapeutics Inc. Common Stock's EV / EBITDA is n/m, based on as-reported figures from SEC (XBRL) filings.
What is Bicara Therapeutics Inc. Common Stock's Net Income (TTM)?
Bicara Therapeutics Inc. Common Stock's Net Income (TTM) is -$185.4M, based on as-reported figures from SEC (XBRL) filings.
What is Bicara Therapeutics Inc. Common Stock's EBITDA?
Bicara Therapeutics Inc. Common Stock's EBITDA is -$201.8M, based on as-reported figures from SEC (XBRL) filings.
What is Bicara Therapeutics Inc. Common Stock's Diluted EPS (TTM)?
Bicara Therapeutics Inc. Common Stock's Diluted EPS (TTM) is -2.80, based on as-reported figures from SEC (XBRL) filings.
What is Bicara Therapeutics Inc. Common Stock's Net Debt?
Bicara Therapeutics Inc. Common Stock's Net Debt is -$497.3M, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · BCAXAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in thousands of USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023
Operating expenses
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income
Interest income
Total other income
Net loss before income taxes
Net loss
Net Loss per share, basic (in usd per share)—
Net Loss per share, diluted (in usd per share)—